Randomized trial findings suggest an uncertain trail ahead for TB digital adherence technologies

Affiliations

¹ Department of Public Health and Community Medicine and Center for Global Public Health, Tufts University School of Medicine, Boston, MA, Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Boston, MA, USA.
² TB Centre, London School of Hygiene & Tropical Medicine, London, UK.
³ Microsoft Research India, Bangalore, Karnataka, India, Everwell Health Solutions, Bangalore, Karnataka, India.
⁴ Montreal Chest Institute, Montreal, QC, Canada, Respiratory Epidemiology and Clinical Research Unit, Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, McGill International Tuberculosis Centre, Montreal, QC, Canada.

Comment

R Subbaraman et al. Int J Tuberc Lung Dis. 2022.

. 2022 Apr 1;26(4):378-379.

doi: 10.5588/ijtld.22.0028.

¹ Department of Public Health and Community Medicine and Center for Global Public Health, Tufts University School of Medicine, Boston, MA, Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Boston, MA, USA.
² TB Centre, London School of Hygiene & Tropical Medicine, London, UK.
³ Microsoft Research India, Bangalore, Karnataka, India, Everwell Health Solutions, Bangalore, Karnataka, India.
⁴ Montreal Chest Institute, Montreal, QC, Canada, Respiratory Epidemiology and Clinical Research Unit, Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, McGill International Tuberculosis Centre, Montreal, QC, Canada.

No abstract available

Comment on

A randomised controlled trial to evaluate a medication monitoring system for TB treatment.
Acosta J, Flores P, Alarcón M, Grande-Ortiz M, Moreno-Exebio L, Puyen ZM. Acosta J, et al. Int J Tuberc Lung Dis. 2022 Jan 1;26(1):44-49. doi: 10.5588/ijtld.21.0373. Int J Tuberc Lung Dis. 2022. PMID: 34969428 Free PMC article. Clinical Trial.